Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2008

Open Access 01-02-2008 | Research article

Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males

Authors: David Findlay, Mellick Chehade, Helen Tsangari, Susan Neale, Shelley Hay, Blair Hopwood, Susan Pannach, Peter O'Loughlin, Nicola Fazzalari

Published in: Arthritis Research & Therapy | Issue 1/2008

Login to get access

Abstract

Introduction

The relationship of circulating levels of receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin (OPG) with the expression of these molecules in bone has not been established. The objective of this study was to measure, in humans, the serum levels of RANKL and OPG, and the corresponding levels in bone of mRNA encoding these proteins.

Methods

Fasting blood samples were obtained on the day of surgery from patients presenting for hip replacement surgery for primary osteoarthritis (OA). Intraoperatively, samples of intertrochanteric trabecular bone were collected for analysis of OPG and RANKL mRNA, using real time RT-PCR. Samples were obtained from 40 patients (15 men with age range 50 to 79 years, and 25 women with age range 47 to 87 years). Serum total RANKL and free OPG levels were measured using ELISA.

Results

Serum OPG levels increased over the age range of this cohort. In the men RANKL mRNA levels were positively related to age, whereas serum RANKL levels were negatively related to age. Again, in the men serum RANKL levels were inversely related (r = -0.70, P = 0.007) to RANKL mRNA levels. Also in the male group, RANKL mRNA levels were associated with a number of indices of bone structure (bone volume fraction relative to bone tissue volume, specific surface of bone relative to bone tissue volume, and trabecular thickness), bone remodelling (eroded surface and osteoid surface), and biochemical markers of bone turnover (serum alkaline phosphatase and osteocalcin, and urinary deoxypyridinoline).

Conclusion

This is the first report to show a relationship between serum RANKL and the expression of RANKL mRNA in bone.
Appendix
Available only for authorised users
Literature
1.
Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, et al: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998, 95: 3597-3602. 10.1073/pnas.95.7.3597.PubMedCentralCrossRefPubMed
2.
Yasuda H, Shima N, Nakagawa N, Mochizuki S-I, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, et al: Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998, 139: 1329-1337. 10.1210/en.139.3.1329.PubMed
3.
Kong Y-Y, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, et al: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999, 402: 304-309. 10.1038/46303.CrossRefPubMed
4.
Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, et al: Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998, 93: 165-176. 10.1016/S0092-8674(00)81569-X.CrossRefPubMed
5.
Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, et al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997, 89: 309-319. 10.1016/S0092-8674(00)80209-3.CrossRefPubMed
6.
Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, et al: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998, 12: 1260-1268.PubMedCentralCrossRefPubMed
7.
Fazzalari NL, Kuliwaba JS, Atkins GJ, Forwood MR, Findlay DM: The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. J Bone Miner Res. 2001, 16: 1015-1027. 10.1359/jbmr.2001.16.6.1015.CrossRefPubMed
8.
Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL: TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000, 106: 1481-1488.PubMedCentralCrossRefPubMed
9.
Takayanagi H: Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med. 2005, 83: 170-179. 10.1007/s00109-004-0612-6.CrossRefPubMed
10.
Holding CA, Findlay DM, Stamenkov R, Neale SD, Lucas H, Dharmapatni AS, Callary SA, Shrestha KR, Atkins GJ, Howie DW, et al: The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants. Biomaterials. 2006, 27: 5212-5219. 10.1016/j.biomaterials.2006.05.054.CrossRefPubMed
11.
Kartsogiannis V, Zhou H, Horwood NJ, Thomas RJ, Hards DK, Quinn JM, Niforas P, Ng KW, Martin TJ, Gillespie MT: Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone. 1999, 25: 525-534. 10.1016/S8756-3282(99)00214-8.CrossRefPubMed
12.
Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P: Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem. 2001, 276: 20659-20672. 10.1074/jbc.M010153200.CrossRefPubMed
13.
Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ, Gillespie MT: Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun. 1999, 265: 144-150. 10.1006/bbrc.1999.1623.CrossRefPubMed
14.
Rogers A, Eastell R: Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab. 2005, 90: 6323-6231. 10.1210/jc.2005-0794.CrossRefPubMed
15.
Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM: Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology. 2001, 40: 623-630. 10.1093/rheumatology/40.6.623.CrossRefPubMed
16.
Crotti TN, Smith MD, Findlay DM, Zreiqat H, Ahern MJ, Weedon H, Hatzinikolous G, Capone M, Holding C, Haynes DR: Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Biomaterials. 2004, 25: 565-573. 10.1016/S0142-9612(03)00556-8.CrossRefPubMed
17.
Hofbauer L, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs LB: Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 1999, 140: 4367-4370. 10.1210/en.140.9.4367.PubMed
18.
Browner WS, Lui LY, Cummings SR: Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001, 86: 631-637. 10.1210/jc.86.2.631.PubMed
19.
Szulc P, Hofbauer LC, Heufelder AE, Roth S, Demas PD: Osteoprotegerin serum levels in man: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab. 2001, 86: 3162-3165. 10.1210/jc.86.7.3162.PubMed
20.
Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R: Austrian Study Group on Normative Values of Bone Metabolism. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone. 2003, 32: 681-686. 10.1016/S8756-3282(03)00090-5.CrossRefPubMed
21.
Naylor KE, Rogers A, Fraser RB, Hall V, Eastell R, Blumsohn A: Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. J Clin Endocinol Metab. 2003, 88: 5361-5365. 10.1210/jc.2003-030486.CrossRef
22.
Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004, 292: 490-495. 10.1001/jama.292.4.490.CrossRefPubMed
23.
Seidel C, Hjertner O, Abildgaard N, Heickendorff L, Hjorth M, Westin J, Nielsen JL, Hjorth-Hansen H, Waage A, Sundan A, et al: Nordic Myeloma Study Group. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood. 2001, 98: 2269-2271. 10.1182/blood.V98.7.2269.CrossRefPubMed
24.
Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, Viniou N, Yataganas X, Goldman JM, Rahemtulla A: Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 2003, 102: 1064-1069. 10.1182/blood-2003-02-0380.CrossRefPubMed
25.
Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, Mayr A, Jocher J, Xu Q, Pietschmann P, et al: Soluble RANKL and risk of nontraumatic fracture. JAMA. 2004, 291: 1108-1113. 10.1001/jama.291.9.1108.CrossRefPubMed
26.
Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, Schlondorff J, Tempst P, Choi Y, Blobel CP: Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem. 1999, 274: 13613-13618. 10.1074/jbc.274.19.13613.CrossRefPubMed
27.
Schlondorff J, Lum L, Blobel CP: Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase. J Biol Chem. 2001, 276: 14665-14674. 10.1074/jbc.M010741200.CrossRefPubMed
28.
Hikita A, Yana I, Wakeyama H, Nakamura M, Kadono Y, Oshima Y, Nakamura K, Seiki M, Tanaka S: Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappa B ligand. J Biol Chem. 2006, 281: 36846-36855. 10.1074/jbc.M606656200.CrossRefPubMed
29.
Hofbauer LC, Schoppet M, Schuller P, Viereck V, Christ M: Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin Endocrinol (Oxf). 2004, 60: 214-219. 10.1046/j.1365-2265.2003.01969.x.CrossRef
30.
Fazzalari NL, Parkinson IH: Femoral trabecular bone of osteoarthritic and normal subjects in an age and sex matched group. Osteoarthritis Cartilage. 1998, 6: 377-382. 10.1053/joca.1998.0141.CrossRefPubMed
31.
Kuliwaba JS, Findlay DM, Atkins GJ, Forwood MR, Fazzalari NL: Enhanced expression of osteocalcin mRNA in human osteoarthritic trabecular bone of the proximal femur is associated with decreased expression of interleukin-6 and interleukin-11 mRNA. J Bone Miner Res. 2000, 15: 332-341. 10.1359/jbmr.2000.15.2.332.CrossRefPubMed
32.
Tsangari H, Findlay DM, Fazzalari NL: Structural and remodeling indices in the cancellous bone of the proximal femur across adulthood. Bone. 2007, 40: 211-217. 10.1016/j.bone.2006.07.007.CrossRefPubMed
33.
Khosla S, Arrighi HM, Melton LJ, Atkinson EJ, O'Fallon WM, Dunstan C, Riggs BL: Correlates of osteoprotegerin levels in women and men. Osteoporos Int. 2002, 13: 394-399. 10.1007/s001980200045.CrossRefPubMed
34.
Oh KW, Rhee EJ, Lee WY, Kim SW, Baek KH, Kang MI, Yun EJ, Park CY, Ihm SH, Choi MG, et al: Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. Clin Endocrinol (Oxf). 2005, 62: 92-98. 10.1111/j.1365-2265.2004.02179.x.CrossRef
35.
Hopwood B, Tsykin A, Findlay DM, Fazzalari NL: Microarray gene expression profiling of human osteoarthritic bone suggests altered bone remodelling, WNT and TGF beta/BMP signalling. Arthritis Res Ther. 2007, 9: R100-10.1186/ar2301.PubMedCentralCrossRefPubMed
36.
Ghosh P, Cheras PA: Vascular mechanisms in osteoarthritis. Best Pract Res Clin Rheumatol. 2001, 15: 693-709. 10.1053/berh.2001.0188.CrossRefPubMed
37.
Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC: Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003, 88: 1024-1028. 10.1210/jc.2002-020775.CrossRefPubMed
38.
Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, et al: A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997, 385: 729-733. 10.1038/385729a0.CrossRefPubMed
39.
Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, Tschopp J: Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med. 1998, 187: 1205-1213. 10.1084/jem.187.8.1205.PubMedCentralCrossRefPubMed
40.
Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K, Zannettino AC: The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res. 2004, 19: 147-154. 10.1359/jbmr.2004.19.1.147.CrossRefPubMed
41.
Nakamichi Y, Udagawa N, Kobayashi Y, Nakamura M, Yamamoto Y, Yamashita T, Mizoguchi T, Sato M, Mogi M, Penninger JM, et al: Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts. J Immunol. 2007, 178: 192-200.CrossRefPubMed
42.
Guo LJ, Xie H, Zhou HD, Luo XH, Peng YQ, Liao EY: Stimulation of RANKL and inhibition of membrane-type matrix metalloproteinase-1 expression by parathyroid hormone in normal human osteoblasts. Endocr Res. 2004, 30: 369-377. 10.1081/ERC-200033719.CrossRefPubMed
43.
Portale AA, Lonergan ET, Tanney DM, Halloran BP: Aging alters calcium regulation of serum concentration of parathyroid hormone in healthy men. Am J Physiol. 1997, 272: E139-E146.PubMed
44.
Holmbeck K, Bianco P, Pidoux I, Inoue S, Billinghurst RC, Wu W, Chrysovergis K, Yamada S, Birkedal-Hansen H, Poole AR: The metalloproteinase MT1-MMP is required for normal development and maintenance of osteocyte processes in bone. J Cell Sci. 2005, 118: 147-156. 10.1242/jcs.01581.CrossRefPubMed
45.
Melhus H: Soluble RANKL and risk of nontraumatic fracture. JAMA. 2004, 291: 2703-10.1001/jama.291.22.2703-a.PubMed
46.
Tsangari H, Findlay DM, Kuliwaba JS, Atkins GJ, Fazzalari NL: Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck. Bone. 2004, 35: 334-342. 10.1016/j.bone.2004.02.006.CrossRefPubMed
Metadata
Title
Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males
Authors
David Findlay
Mellick Chehade
Helen Tsangari
Susan Neale
Shelley Hay
Blair Hopwood
Susan Pannach
Peter O'Loughlin
Nicola Fazzalari
Publication date
01-02-2008
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2008
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2348

Other articles of this Issue 1/2008

Arthritis Research & Therapy 1/2008 Go to the issue

Research article

High sensitivity C-reactive protein is associated with lower tibial cartilage volume but not lower patella cartilage volume in healthy women at mid-life

Research article

Role of resistin as a marker of inflammation in systemic lupus erythematosus

Research article

Indoleamine 2,3-dioxygenase-expressing dendritic cells are involved in the generation of CD4+CD25+regulatory T cells in Peyer's patches in an orally tolerized, collagen-induced arthritis mouse model

Research article

Three-dimensional and thermal surface imaging produces reliable measures of joint shape and temperature: a potential tool for quantifying arthritis

Research article

Human articular chondrocytes produce IL-7 and respond to IL-7 with increased production of matrix metalloproteinase-13

Research article

Rutoside decreases human macrophage-derived inflammatory mediators and improves clinical signs in adjuvant-induced arthritis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits